The plasma clearance of hydroxyethyl starch (HES) depends on the initial molecular weight and the degree of substitution. So far, little attention has been paid to the clinical relevance of the C2/C6 substitution ratio of hydroxyethyl starch.
10 patients with cerebrovascular circulatory disturbance received hemodilution therapy for 10 days, consisting of 10% HES 200/0.5 (mean molecular weight 200 kD, degree of substitution 0.5) with a C2/C6 ratio of 13.4. A second group of 10 patients received a starch solution with identical initial molecular weight and degree of substitution but with a C2/C6 ratio of 5.7.
After the administration of a single dose, no significant differences between the two groups were observed. After repeated administration, significant differences could be detected in hemorheology, coagulation and elimination (p<0.01). The larger C2/C6 ratio led to a higher intravascular mean molecular weight (95 vs. 84 kD), which in turn led to a higher increase in serum concentration during the therapy (14.7 vs.8.6 mg/ml). Hematocrit was lowered more (-30,5 vs. -23,5%) and plasma viscosity was increased more. There was also a more pronounced increase in partial thromboplastin time (+30% vs. +13%) and a factor of 2 larger decrease of factor VIII/von Willebrand factor-complex (p <0.01), which exceeded the dilution effect.
The higher C2/C6 ratio of HES 200/0.5/13.4 slows down enzymatic degradation. After repeated administration of this starch, large molecules accumulate which are inefficiently degraded. The same effect has been observed after therapy with highly-substituted HES. This accumulation of large molecules leads to a beneficial longer lasting volume effect. The disadvantages include an increase in plasma viscosity and coagulation disturbances, which cannot be explained with the respective dilution effect alone. For these reasons, the C2/C6 ratio is of clinical relevance and should be included in the product labeling in the future.
References
1
Symington BE.
Hetastarch and bleeding complications. Ann Intern Med 1986; 105: 627-628
4
Lockwood DN J,
Bullen C,
Machin SJ.
A severe coagulophathy following volume replacement with hydroxyethylstarch in a jehovahs witness. Anaesthesia 1988; 43: 391-393
5
Stump DC,
Strauss RG,
Henriksen RA,
Petersen RE,
Saunders R.
Effects of hydroxyethyl starch on blood coagulation, particularly factor VIII. Transfusion 1985; 25: 349-354
7
Haass A,
Treib J,
Stoll M.
Hemorheological parameters of hydroxyethyl starch 200/0,62 as a basis for hemodilution. Clinical hemorheology 1992; 12 Supp (Suppl. 01) 17-26
8
Haass A,
Stoll M,
Treib J.
Hemodilution in cerebral circulatory disturbances: Indications, implementation, additional drug treatment and alternatives. In: Hamodilution. New aspects in the management of circulatory blood flow. Improvement of macro- and microcirculation
Koscielny J,
Kiesewetter H,
Jung F,
Haass A.
eds.
Berlin, Heidelberg; New York: Springer: 1992. pp 53-114
9
Heilmann L,
Lorch E,
Hojnacki B,
Müntefering H,
Körster H.
Die Speicherung von zwei unterschiedlichen Hydroxyathylstarke-Praparaten in der Plazenta nach Hamodilution bei Patientinnen mit fetaler Mangelentwicklung oder Schwangerschaftshochdruck. Infusionstherapie 1991; 18: 236-243
10
Yoshida M,
Minami Y,
Kishikawa T.
A study of hydroxyethyl starch. Part III. Comparison of metabolic fates between 2-0-hydroxyethyl starch and 6-0-hydroxyethyl starch in rabbits Starch/Starke 1984; 36: 209-212
11
Eigner W-D.
Hydroxyethylstärke, Molmassenbestimmung von Hydroxyethylstärke in Elektrolytlösung nach Temperaturbelastung. Krankenhauspharmazie 1988; 9: 20-22
12
Förster H,
Wicarkzyk C,
Dudziak R.
Bestimmung der Plasmaelimination von Hydroxyäthylstärke und von Dextran mittels verbesserter analytischer Methodik. Infusionstherapie 1981; 2: 88-94
13
Kiesewetter H,
Radtke H,
Schneider R,
Mussler K,
Scheffler A,
SchmidSchönbein H.
Das Mini-Erythrozytenaggregometer: Ein neues Gerät zur schnellen Quantifizierung des Ausmaβes der Erythrozytenaggregation. Biomed Technik 1982; 27: 209-213
14
Jung F,
Roggenkamp HG,
Schneider R,
Kiesewetter H.
Das Kapillarschlauch-Plasmaviskosimeter, ein neues Meβgerät zur Quantifizierung der Blutplasmaviskositat. Biomed Technik 1983; 28: 249-252
15
Jung F,
Koscielny J,
Mrowietz C,
Förster H,
Schimetta W,
Kiesewetter H,
Wenzel E.
Einfluβ der Molekülstruktur von Hydoxyäthylstärke auf die Eliminationskinetik und die Flieβfähigkeit des Blutes bei Probanden. Arzneimittelforschung 1993; 43: 99-105
16
Haass A,
Kroemer H,
Jäger H,
Müller K,
Decker I,
Wagner EM,
Schimrigk K.
Dextran 40 oder HAES 200/0,5? Hämorheologie der Langzeitbehand-lung beim ischämischen zerebralen Insult. Dtsch Med Wschr 1986; 111: 1681-1686
19
Claes Y,
Van Hemelrijck J,
Van Gerven M,
Arnout J,
Vermylen J,
Weidler B,
Van Aken H.
Influence of hydroxyethyl starch on coagulation in patients during the perioperative periode. Anaestn Analg 1992; 75: 24-30
20
Kapiotis S,
Quehenberger P,
Eichler HG,
Schwarzinger I,
Partan C.
Effect of hydroxyethyl starch on the activity of blood coagulation and fibrinolysis in healthy volunteers: comparison with albumin. Crit Care Med 1994; 22: 606-612
21
Batlle J,
Del Rio F,
Fernandez MF,
Martin R,
Borrasca A.
Effect of dextran on factor VIII/von Willebrand factor structur and function. Thromb Haemostas 1985; 54: 697-699
22
Siostrzonek P,
Niessner H,
Deutsch E,
Lechner K,
Koringer C,
Pabinger I,
Heinz R.
Vier Fälle mit erworbenem von Willebrand-Syndrom und mono-klonaler Gamopathie. Langzeitverlauf sowie diagnostische und therapeutische Problematik. 16 Hamophilie Symposion; Hamburg: 1985: 248-256
24
Kuitunen A,
Hynynen M,
Salmenperä M,
Heinonen J,
Vahtera E,
Verkkala K,
Myllylä G.
Hydroxyethyl starch as a prime for cardiopulmonary bypass: effects of two different solutions on haemostasis. Acta Anaesthesiol Scand 1993; 37: 652-658
